Molecular profiling in glioblastoma: Prelude to personalized treatment (original) (raw)
Clinical Significance of Molecular Biomarkers in Glioblastoma
Petr Kavan
The Canadian Journal of Neurological Sciences, 2010
View PDFchevron_right
Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis
tonia cenci
Journal of Personalized Medicine
View PDFchevron_right
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Gabriela kramer-MareK
BioMed Research International, 2017
View PDFchevron_right
Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies
Santosh Kesari
Oncotarget, 2016
View PDFchevron_right
The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma
Valerio Nardone
Clinical Neurology and Neurosurgery, 2016
View PDFchevron_right
MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?
Peter Hau
Disease Markers, 2007
View PDFchevron_right
Molecular diagnostics of gliomas: the clinical perspective
Martin Van Den Bent
Acta Neuropathologica, 2010
View PDFchevron_right
Protein Markers Predict Survival in Glioma Patients
Jean-Eudes Dazard
Molecular & Cellular Proteomics, 2016
View PDFchevron_right
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Martin Van Den Bent
Nature Reviews Neurology, 2009
View PDFchevron_right
A practical review of prognostic correlations of molecular biomarkers in glioblastoma
Jayson Neil
Neurosurgical Focus, 2015
View PDFchevron_right
MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme
Rosa Della Monica
International Journal of Molecular Sciences
View PDFchevron_right
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
Martin Van Den Bent
Acta Neuropathologica, 2012
View PDFchevron_right
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival
Daphne Haas-kogan, David Stokoe
Journal of Neuro-Oncology, 2010
View PDFchevron_right
High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome
George Papavassiliou, Christos Adamopoulos, Christina Piperi
Molecular medicine (Cambridge, Mass.)
View PDFchevron_right
MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study
Paulina Śledzińska
Biomedicines
View PDFchevron_right
Prospective, high-throughput molecular profiling of human gliomas
Leif Ellisen
Journal of Neuro-Oncology, 2012
View PDFchevron_right
Recent advances in the molecular understanding of glioblastoma
Sieger Leenstra
Journal of Neuro-Oncology, 2012
View PDFchevron_right
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)
Dheera Sanadhya
Scientific Reports, 2018
View PDFchevron_right
Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma
Edit Bosnyák
Clinical nuclear medicine, 2017
View PDFchevron_right
Differential Regulation of the EGFR/PI3K/AKT/PTEN Pathway between Low- and High-Grade Gliomas
ALVEIRO ERIRA
Brain Sciences
View PDFchevron_right
Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers
Muhammad Ghazi Abbas
Journal of Oncology
View PDFchevron_right
Prognostic Impact of MGMT Promoter Methylation in Glioblastoma - A Systematic Review
Luigi Maria Larocca
Journal of Cancer Science & Therapy, 2014
View PDFchevron_right
Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications
Enrico Franceschi
The Oncologist, 2017
View PDFchevron_right
Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications
Giovanni Lanza
Oncologist, 2017
View PDFchevron_right
Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma
Pora Kim
Neuro-Oncology
View PDFchevron_right
MGMT promoter methylation in malignant gliomas
Martin Van Den Bent
Targeted Oncology, 2010
View PDFchevron_right
Influence of Intratumor Heterogeneity on the Predictivity of MGMT Gene Promoter Methylation Status in Glioblastoma
Lorena Gurrieri
Frontiers in Oncology, 2020
View PDFchevron_right